Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 70069-834

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 70069-834). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Somerset Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton_pemetrexed 100 mg (Carton 100 mg)

Carton_pemetrexed 100 mg (Carton 100 mg)
Label for Pemetrexed for Injection, USP 100 mg/vial lyophilized powder for solution. The label includes dosage, storage, reconstitution instructions, and caution as a cytotoxic agent. It indicates single-dose vial, intravenous use, Rx only, with labeling by Somerset Therapeutics LLC. The label also notes the product is made in India and includes a barcode and serialization placeholder.*
FDA Label Image

Carton_pemetrexed 500 mg (Carton 500 mg)

Carton_pemetrexed 500 mg (Carton 500 mg)
Label for Pemetrexed for Injection, USP 500 mg/vial, lyophilized powder for solution for intravenous use. The label states the active ingredient pemetrexed disodium equivalent to 500 mg pemetrexed, includes instructions for reconstitution and storage, and warns it is a cytotoxic agent. Manufactured by Somerset Therapeutics LLC, made in India.*
FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
A Kaplan-Meier survival curve comparing overall survival percentages over time in months for two treatment arms: Pemetrexed plus pembrlolizumab plus platinum chemotherapy (A+P+C) and Pemetrexed plus platinum chemotherapy plus placebo (A+C). The chart illustrates survival trends up to 21 months for each group.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A survival probability curve comparing two treatment groups over time in months: Pemetrexed plus Cisplatin (AC) and Gemcitabine plus Cisplatin (GC). The y-axis shows survival probability, and the x-axis shows survival time in months up to 30 months. Patient counts at risk for each group are listed below the graph at various time points.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A survival probability graph comparing two chemotherapy regimens: Pemetrexed + Cisplatin (AC) shown with a solid line, and Gemcitabine + Cisplatin (GC) shown with a dotted line. The X-axis represents survival time in months (0 to 30), and the Y-axis shows survival probability (0.0 to 1.0). The chart also includes a table of patient counts at risk over time for both regimens.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A survival curve chart comparing survival probability over time in months for two treatment groups: Pemetrexed + Cisplatin (solid line) and Gemcitabine + Cisplatin (dotted line). The chart includes a table showing the number of patients at risk at various time points up to 30 months.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier survival curve chart showing survival probability over time (months) for patients treated with Pemetrexed compared to Placebo. The chart includes two lines representing Pemetrexed and Placebo, with survival probability on the vertical axis and time in months on the horizontal axis. Below the graph is a table indicating the number of patients at risk at various time points for each treatment group.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A survival probability Kaplan-Meier curve comparing Pemetrexed and placebo over time in months. The y-axis represents survival probability from 0 to 1, and the x-axis shows survival time up to 42 months. The graph includes patient risk numbers at various time points for both groups, demonstrating survival differences between Pemetrexed and placebo treatments.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A Kaplan-Meier survival probability curve comparing overall survival time (months) for Pemetrexed versus placebo in squamous non-small cell lung cancer (NSCLC) patients, including a table of patients at risk over time from study JMEN.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A survival probability curve comparing Pemetrexed injection versus placebo over survival time in months. The solid line represents Pemetrexed, showing higher survival probability over time compared to the dotted placebo line. The chart includes a table below listing the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
A survival probability chart comparing Pemetrexed plus Cisplatin versus Cisplatin alone over survival time in months. The chart shows survival curves with a higher probability for Pemetrexed plus Cisplatin and includes a table of patients at risk at different time points for both treatment groups.*
FDA Label Image

Label_pemetrexed 100 mg (Label 100 mg)

Label_pemetrexed 100 mg (Label 100 mg)
Label for Pemetrexed for Injection, USP 100 mg per vial, a lyophilized powder for intravenous use. The single-dose vial contains pemetrexed disodium equivalent to 100 mg pemetrexed. Manufactured by Somerset Therapeutics LLC, with storage instructions and caution that it is a cytotoxic agent. Barcode and lot coding information are present.*
FDA Label Image

Label_pemetrexed 500 mg (Label 500 mg)

Label_pemetrexed 500 mg (Label 500 mg)
Label for Pemetrexed for Injection, USP, 500 mg per vial. The vial contains lyophilized powder for intravenous injection. The label includes storage instructions, caution as a cytotoxic agent, and is manufactured for Somerset Therapeutics LLC in Somerset, NJ, with product made in India. The label also indicates single-dose vial use and Rx only.*
FDA Label Image

Structural Formula (Pemetrexed F01 V01)

Structural Formula (Pemetrexed F01 V01)
Chemical structure of Pemetrexed disodium, shown as a molecular diagram with labeled sodium ions (Na+) and water molecules (2.5 H2O). The structure displays interconnected rings and functional groups characteristic of the active pharmaceutical ingredient.*
FDA Label Image

Table 11 (Table 11)

Table 11 (Table 11)
A data table titled 'Table 11: Efficacy Results in Study JMDB' comparing efficacy parameters between Pemetrexed for injection plus Cisplatin (N=862) and Gemcitabine plus Cisplatin (N=863). Parameters include Overall Survival, Progression-Free Survival, and Overall Response Rate with associated median months, hazard ratios, and confidence intervals.*
FDA Label Image

Table-12 (Table 12)

Table-12 (Table 12)
Data table comparing median months and hazard ratios (HR) with 95% confidence intervals (CI) for histologic subgroups of non-squamous and squamous cell lung cancers treated with Pemetrexed plus Cisplatin versus Gemcitabine plus Cisplatin. Subgroups include adenocarcinoma, large cell, non-squamous not otherwise specified, and squamous cell, with sample sizes and notes on statistical adjustments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.